Pharmasset has achieved a triumph on signing an agreement with F. Hoffmann La-Roche for the development of its nucleoside polymerase inhibitor, PSI-6130 for the treatment of chronic hepatitis C virus (HCV) infections. This is very positive news for Pharmasset, providing an endorsement of its nucleoside polymerase inhibitors and a very significant financial boost. Pharmasset also gains a large and experienced partner having considerable expertise and interest in anti-HCV therapeutics.